Cargando…

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD

The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 μg twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with moderate-to-severe COPD. Patients received AB/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watz, Henrik, Troosters, Thierry, Beeh, Kai M, Garcia-Aymerich, Judith, Paggiaro, Pierluigi, Molins, Eduard, Notari, Massimo, Zapata, Antonio, Jarreta, Diana, Garcia Gil, Esther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574699/ https://www.ncbi.nlm.nih.gov/pubmed/28883722 http://dx.doi.org/10.2147/COPD.S143488

Ejemplares similares

Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
por: Koopman, Maud, et al.
Publicado: (2022)

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
por: Beeh, Kai M, et al.
Publicado: (2014)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
por: Sethi, Sanjay, et al.
Publicado: (2019)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
por: D’Urzo, Anthony D, et al.
Publicado: (2019)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
por: Singh, Dave, et al.
Publicado: (2014)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015)

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
por: Bateman, Eric D., et al.
Publicado: (2015)

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison
por: Medic, Goran, et al.
Publicado: (2016)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
por: Miravitlles, Marc, et al.
Publicado: (2016)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients
por: Tzani, Panagiota, et al.
Publicado: (2011)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: D’Urzo, Anthony, et al.
Publicado: (2017)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
por: Singh, Dave, et al.
Publicado: (2017)

An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
por: Zhang, Hong, et al.
Publicado: (2022)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
por: Matera, Maria Gabriella, et al.
Publicado: (2016)

Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD
por: Alter, Peter, et al.
Publicado: (2019)

New Pharmacologic Perspectives in Pneumology: Beclomethasone-Formoterol Extrafine
por: Paggiaro, Pierluigi
Publicado: (2009)

Clinical use of aclidinium in patients with COPD
por: Reid, Debra J, et al.
Publicado: (2014)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

The Effect of Aclidinium on Symptoms Including Cough in Chronic Obstructive Pulmonary Disease: A Phase 4, Double-Blind, Placebo-controlled, Parallel-Group Study
por: Smith, Jaclyn A., et al.
Publicado: (2019)

Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)
por: Watz, Henrik, et al.
Publicado: (2016)

Hyperinflation and its management in COPD
por: Puente-Maestu, Luis, et al.
Publicado: (2006)

Cardiovascular effects of exercise induced dynamic hyperinflation in COPD patients—Dynamically hyperinflated and non-hyperinflated subgroups
por: Lukacsovits, Jozsef, et al.
Publicado: (2023)

Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial
por: Divo, Miguel J., et al.
Publicado: (2020)

Prediction of air trapping or pulmonary hyperinflation by forced spirometry in COPD patients: results from COSYCONET
por: Alter, Peter, et al.
Publicado: (2020)

Longitudinal changes in lung hyperinflation in COPD
por: Park, Jimyung, et al.
Publicado: (2017)

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
por: Suppli Ulrik, Charlotte
Publicado: (2012)

Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2015)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
por: Contoli, Marco, et al.
Publicado: (2016)

Effects of pharmacological and non-pharmacological interventions on physical activity outcomes in COPD: a systematic review and meta-analysis
por: Megaritis, Dimitrios, et al.
Publicado: (2023)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
por: Plate, Tanja, et al.
Publicado: (2020)

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD
por: Herth, Felix, et al.
Publicado: (2020)

Diaphragmatic excursion correlates with exercise capacity and dynamic hyperinflation in COPD patients
por: Shiraishi, Masashi, et al.
Publicado: (2020)

Resting hyperinflation and emphysema on the clinical course of COPD
por: Kim, Yeon Wook, et al.
Publicado: (2019)

No room to breathe: the importance of lung hyperinflation in COPD
por: Thomas, Mike, et al.
Publicado: (2013)

Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD
por: Manoharan, Arvind, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5jddmmanln203qvvl074cv8tpf